Toshinobu Hayashi

15PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 29, 2026
Effectiveness of continuous pharmacist intervention at maintaining dose intensity in postoperative adjuvant S-1 chemotherapy for gastric cancer: a multicentre retrospective study.

|Jul 22, 2026
Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.

|Jun 11, 2026
Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study.

|Jan 15, 2026
Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.

Akari Yamashita, Toshinobu Hayashi, Mototsugu Shimokawa

|Nov 25, 2025
Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study.

Yudai Harimitsu, Toshinobu Hayashi, Mototsugu Shimokawa

|Sep 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Toshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata

Pageof 3

Frequent Collaborators

2 joint publications

Takashi Egawa

2 joint publications

Chihiro Shiraishi

1 joint publications

Koji Matsumoto

1 joint publications

Miyu Eguchi